title: Responsiveness of three newly established human colorectal cancer cell lines to transforming growth factors beta 1 and beta 2.
abstract: We have established 3 new human colorectal cancer cell lines (LS411N, LS513, and LS1034) from clinical biopsy samples. These lines are tumorigenic and grow s.c. as adenocarcinomas in nude mouse xenografts. Specific marker chromosomes are observed in each line. Carcinoembryonic antigen is expressed at the surface of all 3 lines, but with marked quantitative differences. Indeed, less than 10% of the cells from the HT-29 line used as a reference express carcinoembryonic antigen while more than 90% of the LS1034 cells do so. LS513 and LS1034 consistently express HLA class I antigens and intercellular adhesion molecule 1 which are not detected at the surface of the LS411N cells. No expression of HLA class II antigens DR, DQ, and DP has been measured on any of the lines. All three lines grow well in 5% fetal calf serum medium without addition of exogenous growth factors. The LS1034 line has been adapted to growth in serum-free conditions and exhibits increased clonogenicity when cells are seeded in serum-free methylcellulose medium, as compared with medium containing 5% fetal calf serum. The LS513 and LS1034 lines have proved to be of particular interest since they respond to the growth-inhibitory action of TGF-beta 1 and TGF-beta 2 in both liquid and semisolid medium. Both factors were, at pM concentrations, equipotent inhibitors of LS1034 cell proliferation. In contrast, higher concentrations of TGF-beta 1 are inhibitory for proliferation of LS513 cells, whereas TGF-beta 2 has no effect on the growth of these cells in liquid assay. On this basis, using appropriate anti-TGF-beta 1 and anti-TGF-beta 1 IgY, we developed a bioassay for TGF-beta 1 and TGF-beta 2. Two of the three lines have indeed been shown to produce latent-TGF-beta 1 activity.
authors.affiliation: Swiss Institute for Experimental Cancer Research, Epalinges sur Lausanne.
authors.forename: L
authors.initials: L
authors.lastname: Suardet
authors.forename: A C
authors.initials: AC
authors.lastname: Gaide
authors.forename: J M
authors.initials: JM
authors.lastname: Calmès
authors.forename: B
authors.initials: B
authors.lastname: Sordat
authors.forename: J C
authors.initials: JC
authors.lastname: Givel
authors.forename: J F
authors.initials: JF
authors.lastname: Eliason
authors.forename: N
authors.initials: N
authors.lastname: Odartchenko
mesh_terms: D000328:Adult; D000954:Antigens, Surface / Q000032:analysis; D015179:Colorectal Neoplasms / Q000235:genetics / Q000276:immunology / Q000473:pathology*; D006801:Humans; D007621:Karyotyping; D008297:Male; D008875:Middle Aged; D009368:Neoplasm Transplantation; D016212:Transforming Growth Factor beta / Q000032:analysis / Q000494:pharmacology*; D014183:Transplantation, Heterologous; D014407:Tumor Cells, Cultured / Q000187:drug effects
chemical_list: D000954:Antigens, Surface; D016212:Transforming Growth Factor beta